Related Experiment Video

Updated: Jun 23, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Pravastatin and cardiovascular risk in moderate chronic kidney disease

Haruo Nakamura1, Kyoichi Mizuno, Yasuo Ohashi

  • 1Mitsukoshi Health and Welfare Foundation, STEC Jyoho Building, 1-24-1 Nishishinjuku Shinjuku, Tokyo, 160-0023, Japan. nakamura@mhwf.or.jp

Atherosclerosis
|May 9, 2009
PubMed

Insights

Patients with moderate chronic kidney disease (CKD) face higher cardiovascular disease (CVD) risks. Pravastatin significantly reduced CVD events and improved renal function in these patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a significant concern in patients with chronic kidney disease (CKD).
  • The efficacy of statin therapy in hypercholesterolemic patients with CKD requires further investigation.
  • Japanese guidelines exclude patients with severe kidney disease from statin use.

Purpose of the Study:

  • To investigate the association between chronic kidney disease (CKD) and cardiovascular disease (CVD).
  • To evaluate the effect of low-dose pravastatin on CVD prevention and renal function in Japanese hypercholesterolemic patients with CKD.

Main Methods:

  • A post hoc analysis of the MEGA Study involving 7196 hypercholesterolemic patients.
  • Patients were categorized based on estimated glomerular filtration rate (eGFR): normal/mild CKD (eGFR ≥60) or moderate CKD (30-60 mL/min/1.73m²).
  • The study assessed the primary prevention of CVD and changes in renal function over 5 years with low-dose pravastatin (10-20mg daily).

Main Results:

  • Moderate CKD patients exhibited a 35-49% higher incidence of CVD events compared to normal/mild CKD patients.
  • Pravastatin significantly reduced coronary heart disease (CHD) by 48%, stroke by 73%, CVD by 55%, and total mortality by 51% in the moderate CKD group.
  • Patients with moderate CKD receiving pravastatin showed a significantly greater increase in eGFR (+6.3%) compared to diet alone (+5.1%) over follow-up.

Conclusions:

  • Moderate CKD is associated with an elevated risk of CVD.
  • Pravastatin treatment significantly reduces CVD risk and mortality in patients with moderate CKD.
  • Pravastatin demonstrates beneficial effects on renal function in patients with moderate CKD.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...